Top

News & Events

Client News

Client News

Microbiotica to Present at Top Microbiome Conferences

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome conferences throughout May and June.

Read more »

Clinigen and Mitsubishi Tanabe initiate European Managed Access Program for edaravone to treat ALS

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).

Read more »

F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-class Immuno-oncology Bispecific Antibody

Cambridge, UK – F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies, today announced successful dosing of the first patient with FS118 in a Phase I clinical trial.

Read more »

Seventure Partners Life Sciences Corporate Update January - April 2018

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces its corporate update for the period January-April 2018.

Read more »

New Insights into Hookipa’s TheraT® Replicating Viral Vector Platform published in Immunity

Vienna, Austria - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases, today announces the publication of a new preclinical study of its TheraT® replicating viral platform in the May edition of the prestigious international peer-reviewed journal Immunity1.

Read more »

Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients

Irvine, CA, Amsterdam, Netherlands – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer, has selected the MammaPrint® Breast Cancer Risk of Recurrence test and BluePrint® Molecular Subtyping test for use in its 18 French Comprehensive Cancer Centers (FCCC).

Read more »

Immatics Appoints Stephen Eck as Chief Medical Officer US

Houston, Texas – Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Stephen Eck, M.D., Ph.D. as Chief Medical Officer (CMO) at Immatics US, Inc. (Houston, Texas), effective immediately.

Read more »

Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio

TÜBINGEN, Germany — Acousia Therapeutics (Acousia), a leader in the discovery and development of novel therapies in inner ear-related diseases and pathologies, today announced the closing of a €10 million Series B financing round to advance its pipeline of preclinical drug candidates into clinical stage.

Read more »

Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

Read more »

Astex’s Harren Jhoti made Fellow of the Royal Society

Cambridge, UK - Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti Ph.D., co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been elected a Fellow of the Royal Society in recognition of his outstanding contribution to drug discovery research and science in general.

Read more »

SkinBioTherapeutics finalises plans for human study of cosmetic application and progresses manufacturing scale-up

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health,  is pleased to provide the following update:

Read more »

Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing

Cambridge, UK — Crescendo Biologics Ltd (Crescendo) the developer of multi-functional biologics with a focus on novel targeted T-cell engagers, announced today that it has completed a $70 million (€57 million) Series B financing.

Read more »

Belgian Microbiome Spin-off A-Mansia Announces €13m First Close of Series A Financing

Louvain-la-Neuve, Belgium – A-Mansia Biotech S.A. (A-Mansia), the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. muciniphila) bacterium, today announces a €13 million first close of its Series A financing, led by Seventure Partners. The financing round remains open for additional investment.

Read more »

Rapid Detection of Pathogen and Antibiotic Resistance with DNAe’s LiDia® Bloodstream Infection (BSI) Technology

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, announces new data generated with its LiDia® Bloodstream Infection (BSI) technology, currently in development. The LiDia® BSI method was demonstrated to detect pathogen and antibiotic resistance in samples collected from patients after receiving antibiotic therapy. Time to detection by the LiDia® BSI method was significantly shorter (hours vs. days) compared to standard-of-care blood culture testing.

Read more »

Recce Pharmaceuticals: Pharmaceutical Expert Joins Board of Directors

Sydney, Australia - Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, today announced the appointment of Dr John Prendergast to its Board as an independent Non-Executive Director.

Read more »

BioScience Managers: Downing FOUR VCT invests £1.14 million in ADC Biotechnology Ltd

London, UK – London-based investment management firm, Downing LLP, and BioScience Managers Limited, the international healthcare investment firm and advisers to the Downing FOUR VCT, today announce the completion of a new £1.14 million investment in Wales-based ADC Biotechnology Ltd.

Read more »

Additional AU$861,590 R&D Tax Incentive Rebate for RECCE® 327 Antibiotic

SYDNEY, Australia - Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, today confirmed it has received an additional $861,590 from the Australian Government for its overseas Advanced Drug Development expenditure in FY2017 under the Australian Government’s Research and Development (R&D) Tax Incentive program.

Read more »

Xellia Pharmaceuticals Appoints Craig Boyd as President, Xellia US as it Expands its Commercial Organization in Preparation for the Launch of its Value-Added Anti-Infective Drug Products

Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’ or the ‘Company’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, announced today that it has appointed Craig Boyd to the new leadership role of President, Xellia US. Craig will be responsible for leading the growth of Xellia’s US business as the Company prepares to launch its pipeline of value-added anti-infective drug products into the US market. Xellia is also significantly expanding its commercial organization with a new office planned in Chicago to complement its increased US manufacturing capabilities as its facilities in Cleveland Ohio come into full operation in 2018.

Read more »

SkinBioTherapeutics’ technology, SkinBiotix®, shows positive results in cream formulation

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, announces that the ‘cream’ formulation of its SkinBiotix® technology has passed effectiveness studies in models of skin. The cream formulation will now undergo further testing for stability in the coming weeks.

Read more »

Crescendo Biologics Reaches First Major Milestone in Strategic Collaboration with Takeda

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the developer of multifunctional biologics, including targeted T-cell engagers, today announced that it has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502).

Read more »

DNAe to Present New Data and Preview its Blood-to-Result Test for Bloodstream Infection at ECCMID 2018

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections that can lead to sepsis, announces that new data will be presented on its LiDia® Bloodstream Infection (BSI) test1,2 at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Madrid, Spain, 21-24th April, 2018.

Read more »

PTX-200 Phase 1b Breast Cancer Trial Results Prescient’s Most Significant Clinical Milestone to Date

Melbourne, Australia - Clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX) is delighted to announce that the patients evaluable for efficacy in the PTX-200 Phase 1b breast cancer trial exhibited an overall response rate of 50%, against an expected industry average response rate of 25% with paclitaxel alone.  In patients with locally advanced disease, two patients had pathologic complete responses (40%), meaning a complete eradication of cancer.

Read more »

Forbion participates in £29M Series B Financing of Enterprise Therapeutics to Advance its Ion Channel Modulators for the treatment of Cystic-fibrosis, COPD and severe asthma

Naarden, The Netherlands – Forbion, one of the leading European life science venture capital firms, today announces that it participated together with new investors Versant Ventures and Novartis Venture Fund and existing investors Epidarex Capital and IP Group in an oversubscribed £29M investment round in the UK biotech company Enterprise Therapeutics. The investment will fund the Company’s drug discovery pipeline of muco-regulatory therapies into clinical development, enabling new treatment options for cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma.

Read more »

MerLion Pharmaceuticals: Positive Phase II Data of Finafloxacin Antibiotic Published in Three Papers in Antimicrobial Agents and Chemotherapy

Singapore - MerLion Pharmaceuticals (MerLion) today announced that three papers summarizing clinical data from its Phase II clinical trial with finafloxacin in complicated urinary tract infections (cUTIs) have been published online in the peer-reviewed journal Antimicrobial Agents and Chemotherapy and in the print version of the April issue. Finafloxacin is a novel antibiotic that, as well as an outstanding safety profile, demonstrates strong antibacterial activity under acidic conditions; differentiating it from other existing antibiotic therapies and offering new, exciting treatment opportunities.

Read more »

NorthSea Therapeutics: Potential of icosabutate as a novel approach to the treatment of NASH highlighted in late-breaker at The International Liver CongressTM 2018

Naarden, The Netherlands – NorthSea Therapeutics B.V., (‘NST’) a newly established Dutch biotech company aiming to develop novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, announces the publication of a late-breaker abstract and poster to be presented at The EASL International Liver CongressTM 2018 in Paris on 12-14 April.

Read more »